Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.62 |
| ▸ | IGF2R | P11717 | 4/20 | 0.49 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
| ▸ | UMPS | P11172 | 2/20 | 0.38 |
| ▸ | ADSS2 | P30520 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14928336 | 1.00 | FBP1 (0.62) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL17789074 | 1.00 | FBP1 (0.62) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL14945941 | 1.00 | FBP1 (0.62) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL15293070 | 1.00 | FBP1 (0.62) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL15760645 | 0.88 | FBP1 (0.47) | FBP1P2RY2P2RY6 | |
| SCHEMBL15293068 | 0.86 | FBP1 (0.46) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL14945942 | 0.86 | FBP1 (0.46) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL15293069 | 0.86 | FBP1 (0.46) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL15745771 | 0.86 | FBP1 (0.46) | FBP1IGF2RAMDHD2P2RY2P2RY6 | |
| SCHEMBL17789077 | 0.86 | FBP1 (0.46) | FBP1IGF2RAMDHD2P2RY2P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572897-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160158385-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-06-09 | — | — | US | disclosed |
| US-20140148502-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158385-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | POLRMT, POLN, PHAX | FBP1 2938/4885IGF2R 2220/4885AMDHD2 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.